Prostate cancer is one of the most frequently diagnosed cancers and the second leading cause of cancer death in American men. Current treatments for androgen-independent prostate cancer have not shown a definitive increase in survival. The treatment options employed for patients with advanced and metastatic prostate cancer are limited. Stat3 is a critical mediator of oncogenic signaling, which is active in 82% of prostate cancers as well as many other cancers. However, drugs targeting Stat3 have not been used to treat prostate cancer. Our goal is to develop a novel, potent inhibitor of Stat3 as a therapeutic drug for prostate cancer therapy. Developing a novel and promising treatment for prostate cancer will be greatly helpful both in terms of single agent treatment and as part of a combination therapy. We propose a novel strategy to inhibit Stat3, which could be very useful in development of prostate cancer therapy, and have developed a G-quartet oligodeoxynucleotide (GQ-ODN), T40214, as a lead compound that preferentially inhibits the DNA-binding activation of Stat3 among STAT protein members, resulting in the suppression of the anti-apoptotic genes, bcl-x and Mcl-1, in cancer cells. We also have constructed a model of GQ-ODN binding onto Stat3a dimer for rational drug design. The molecular model suggests that the GQ-ODN insert between the two SH2 domains of Stat3 dimer resulting in destabilization of the homodimers. We further show that T40214 and its derivative, T40231, have dramatic in vivo effects on prostate cancer growth in nude mice when the agent is given by intravenous or intraperitoneal injections, dramatically retarding tumor growth and significantly increasing the length of survival time. Also GQ-ODNs greatly increase the number of apoptotic cells in tumors, showing the agents using apoptosis to eliminate tumor cells.
The Specific Aims designed to achieve this objective are outlined as below. (1) To develop a potent inhibitor of Stat3 to suppress the growth of prostate cancer cells in cell culture. The strategy to achieve this specific aim contains three parts: (i) rational drug design, which will include structure-based drug design and rational optimization, (ii) oligonucleotide synthesis, and (iii) Stat3 activity assays in vitro. (2) To develop an optimally effective intracellular and intranuclear delivery system for GQ-ODNs. In this aim, we will use our novel drug delivery system to determine the optimum conditions for intracellular delivery of G-quartet inhibitors, e.g. T40214 and its derivatives, in vivo. (3) To determine the effect of GQ-ODNs on Stat3 activity and the growth of prostate tumors in vivo. Using nude mice tumor xenograft assays, we will determine whether GQ-ODNs, T40214 and its derivatives, can block or control the growth of prostate tumors in xenografted mice; whether the anti-tumor effects of GQ-ODNs are on both non-androgen and androgen responsiveness; whether the suppression of tumor growth for GQ-ODNs is mediated by enhanced apoptosis of tumor cells.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Woodhouse, Elizabeth
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Schools of Medicine
United States
Zip Code
Zhou, Zhou; Gushiken, Francisca C; Bolgiano, Doug et al. (2013) Signal transducer and activator of transcription 3 (STAT3) regulates collagen-induced platelet aggregation independently of its transcription factor activity. Circulation 127:476-485
Reddy, Kavitha Ramasamy; Guan, Yongli; Qin, Guoting et al. (2011) Combined treatment targeting HIF-1ýý and Stat3 is a potent strategy for prostate cancer therapy. Prostate 71:1796-809
Guan, Yongli; Reddy, Kavitha Ramasamy; Zhu, Qiqing et al. (2010) G-rich oligonucleotides inhibit HIF-1alpha and HIF-2alpha and block tumor growth. Mol Ther 18:188-97
Zhou, Zhou; Bernardo, Aubrey; Zhu, Qiqing et al. (2009) A G-quartet oligonucleotide blocks glycoprotein Ib-mediated platelet adhesion and aggregation under flow conditions. Thromb Haemost 102:529-37
Weerasinghe, Priya; Li, Yifei; Guan, Yongli et al. (2008) T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate 68:1430-42
Zhu, Qiqing; Jing, Naijie (2007) Computational study on mechanism of G-quartet oligonucleotide T40214 selectively targeting Stat3. J Comput Aided Mol Des 21:641-8
Weerasinghe, Priya; Garcia, Gabriela E; Zhu, Qiqing et al. (2007) Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 31:129-36
Jing, Naijie; Zhu, Qiqing; Yuan, Ping et al. (2006) Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther 5:279-86
Tweardy, David J; Jing, Naijie (2006) Enhancing or eliminating signals for cell survival to treat disease. Trans Am Clin Climatol Assoc 117:33-51; discussion 51-2
Jing, Naijie; Tweardy, David J (2005) Targeting Stat3 in cancer therapy. Anticancer Drugs 16:601-7